# OnCo record nct05980481 (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/nct05980481/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "nct05980481", "NCT05980481" ;
  schema:name "A Study of RC48-ADC Combination Therapies as First-line Treatment in Advanced Metastatic Gastric Cancer"@en ;
  schema:description "A phase 2/3 trial of Trastuzumab, Toripalimab, Oxaliplatin and Capecitabine in gastric & gastro-oesophageal junction cancer, run by RemeGen Co., Ltd., active and no longer recruiting."@en ;
  schema:url <https://onco.cc/trials/nct05980481/> ;
  schema:dateModified "2026-09-16"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT05980481> ;
  onco:status "active" ;
  onco:tag "pipeline", "ctgov-ingest" ;
  onco:phase "2/3" ;
  schema:startDate "2023-08-04" ;
  onco:cancers <https://onco.cc/cancers/gastric/> ;
  onco:technologies <https://onco.cc/technologies/checkpoint-inhibitor/>, <https://onco.cc/technologies/monoclonal-antibody/> ;
  onco:drugs <https://onco.cc/drugs/trastuzumab/>, <https://onco.cc/drugs/toripalimab/>, <https://onco.cc/drugs/oxaliplatin/>, <https://onco.cc/drugs/capecitabine/> ;
  onco:companies <https://onco.cc/companies/remegen/> .